1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

Acadia's Nuplazid Could Have The Alzheimer's R&D Curse

 
• By Lucie Ellis-Taitt

Acadia's Nuplazid (pimavanserin) has met its primary endpoint in a Phase II study in patients with Alzheimer’s disease psychosis – but a secondary endpoint miss in the same study has triggered alarm bells for future development of the product in Alzheimer's, a historically risky scene, marred by many Phase III failures.

Acadia Pharmaceuticals Inc. has reported mixed Phase II results for its experimental Alzheimer's drug, pimavanserin, at a time when the diseases space is being watched with great interest following the recent late-stage failure of Eli Lilly & Co.'s solanezumab.

While Acadia presented positive data for pimavanserin, with top-line results showing that the drug met its primary endpoint in the Phase II -019 study in patients with Alzheimer’s disease psychosis,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

 
• By Sushmita Panda

Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.

Lilly To Diversify Pain Pipeline With SiteOne Acquisition

 
• By Joseph Haas

Deal snapshot: With several internal non-opioid pain candidates in Phase II or earlier, Lilly looks to add R&D potential in pain with $1bn buyout of SiteOne.

Angelini Advances Brain Health Ambitions With GRIN Pact

 
• By Kevin Grogan

The Italian drugmaker gets rights to Phase III-ready asset radiprodil.

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.

More from Therapy Areas

Summit’s Ivonescimab Shows Significance On PFS, But Not Overall Survival

 
• By Joseph Haas

In a study intended to show similar benefit in western patients, PD-1/VEGF-targeting ivonescimab met a progression-free survival endpoint, but missed on OS.

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By Kevin Grogan

One Phase III trial hits but a second study misses by a mile.

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

 
• By Sushmita Panda

Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.